Saligren 84 capsules 30 mg for dry mouth (Sjogren's syndrome, cevimeline, Evoxac)

General information on Japanese Saligren capsules 30 mg for dry mouth (Sjogren's syndrome, cevimeline, Evoxac)

Package details: 84 capsules

Manufacturer: Nippon Kayaku Co., Ltd., Japan

Active ingredient: cevimeline hydrochloride hydrate (chemical formula (C10H17NOS)2. 2HCl. H2O)

Medical effect: Saligren capsules are effective for the treatment of dry mouth in the patients with Sjogren's syndrome.

Contraindications and precautions: do not use for the following categories of patients:

• pregnant and breastfeeding women,
• patients with ischemic heart disease (myocardial infarction, angina pectoris etc.),
• patients with bronchial asthma or chronic obstructive pulmonary disease,
• patients with gastrointestinal obstruction or urinary bladder neck obstruction,
• patients with epilepsy,
• patients with Parkinsonian syndrome or Parkinson's disease,
• patients with iritis.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

As this medicine may cause miosis, patients should take care when driving a car during the evening, or operating dangerous machinery in a dark place.

Dosage and administration of Saligren capsules 30 mg from Japan for dry mouth (Sjogren's syndrome, cevimeline, Evoxac)

For adults, take 1 capsule (30 mg of the active ingredient) 3 times a day after meals.

How effective are Saligren capsules 30 mg from Japan for dry mouth (Sjogren's syndrome, cevimeline, Evoxac)?

Each Saligren capsule contains 30 mg of cevimeline hydrochloride hydrate, a parasympathomimetic and muscarinic agonist. It works by activating M1 and M3 receptors of the parasympathetic nervous system. Saligren capsules effectively treat the oral dryness by stimulating secretion of the salivary glands and promoting salivation.

Who should take Saligren capsules 30 mg from Japan?

Studies showed that 30 mg capsules of cevimeline hydrochloride within 52 weeks have increased salivary flow and improved subjective and objective symptoms in patients with Sjogren's syndrome (A. Shiozawa. Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): A review of its pharmacological profiles and clinical potential in xerostomia (in Japanese language). Folia Pharmacologica Japonica, 2002, November, 120(4): 253-8). Moreover, cevimeline hydrochloride is currently used for the treatment of dry mouth in patients with psychosomatic oral disease.